Epidermal growth factor receptor mutation
Showing 26 - 50 of >10,000
Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))
Recruiting
- Breast Cancer
- HS-10352 combined with fulvestrant (Stage 1)
- HS-10352 combined with fulvestrant (Stage 2)
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 15, 2022
Lung Tumors, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung Trial in Guangzhou (Icotinib)
Recruiting
- Lung Neoplasms
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 29, 2021
NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)
Active, not recruiting
- Non-Small Cell Lung Cancer
-
Kogarah, Australia
- +29 more
Oct 20, 2022
Advanced Non Small Cell Lung Cancer Trial in Changchun, Shanghai, Hangzhou (D-0316)
Active, not recruiting
- Advanced Non Small Cell Lung Cancer
-
Changchun, Jilin, China
- +2 more
Apr 29, 2022
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Furmonertinib 160 mg, Q.D.
-
Chongqing, Chongqing, China
- +2 more
Sep 16, 2022
NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)
Not yet recruiting
- NSCLC
- EGF-R Positive Non-Small Cell Lung Cancer
- Icotinib
- +3 more
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Nov 28, 2021
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)
Active, not recruiting
- NSCLC Stage IIIB
- +4 more
-
Hong Kong, Hong Kong
- +8 more
Jan 10, 2023
NSCLC Trial in Shanghai (TY-9591(10mg,40mg) qd. po)
Recruiting
- NSCLC
- TY-9591(10mg,40mg) qd. po
-
Shanghai, ChinaShanghai Chest Hospital
Nov 7, 2021
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Leuven (Local ablative therapy)
Recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Local ablative therapy
-
Leuven, BelgiumUZLeuven
Oct 21, 2021
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer Trial in Philadelphia (Palbociclib, Olaparib,
Recruiting
- Metastatic Breast Cancer
- +4 more
- Palbociclib
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 20, 2021
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
EGFR Positive NSCLC Trial in Korea, Republic of (EGFR)
Active, not recruiting
- EGFR Positive Non-small Cell Lung Cancer
-
Anyang, Gyeonggi-do, Korea, Republic of
- +7 more
Jul 13, 2021
NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- (no location specified)
Mar 27, 2023
Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)
Active, not recruiting
- Non Small Cell Lung Cancer
-
Durham, North CarolinaDuke University Medical Center
May 23, 2022
NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)
Completed
- Non-small Cell Lung Cancer With EGFR-Activating Mutations
- Dacomitinib (PF-00299804)
- Gefitinib
-
Beijing, China
- +51 more
Feb 10, 2022
Temporomandibular Joint Disorders Trial in Alexandria (Nd-YAG Fotona, Epidermal Growth Factor)
Enrolling by invitation
- Temporomandibular Joint Disorders
- Nd-YAG Fotona
- Epidermal Growth Factor
-
Alexandria, الإسكندرية, EgyptAlexandria University
Sep 13, 2023
Concordance of Detecting EGFR Mutation by Circulating Tumour
Completed
- NSCLC (Non-small Cell Lung Cancer)
-
Punjab, Chandigarh, India
- +13 more
Jun 4, 2020